Extended report: Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

Objectives To summarise existing evidence on a target oriented approach for rheumatoid arthritis (RA) treatment. Methods We conducted a systematic literature search including all clinical trials testing clinical, functional, or structural values of a targeted treatment approach. Our search covered Medline, Embase and Cochrane databases until December 2008 and also conference abstracts (2007, 2008). Results The primary search yielded 5881 citations; after the selection process, 76 papers underwent detailed review. Of these, only seven strategic clinical trials were extracted: four studies randomised patients to routine or targeted treatment, two compared two different randomised targets and one compared targeted treatment to a historical control group. Five trials dealt with early RA patients. All identified studies showed significantly better clinical outcomes of targeted approaches than routine approaches. Disability was reported in two studies with no difference between groups. Four studies compared radiographic outcomes, two showing significant benefit of the targeted approach. Conclusion Only few studies employed randomised controlled settings to test the value of treatment to a specific target. However, they provided unanimous evidence for benefits of targeted approaches. Nevertheless, more data on radiographic and functional outcomes and on patients with established RA are needed.

[1]  H. H. Kuper,et al.  A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry , 2011, Annals of the rheumatic diseases.

[2]  B. Dijkmans,et al.  Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial , 2011, Rheumatology.

[3]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.

[4]  D. Atar,et al.  Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study , 2011, Annals of the rheumatic diseases.

[5]  M. Dougados,et al.  Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort , 2011, Annals of the rheumatic diseases.

[6]  L. Coates,et al.  Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis , 2010, Annals of the rheumatic diseases.

[7]  B Combe,et al.  Extended Report , 2022 .

[8]  P. Emery,et al.  Bone loss in very early inflammatory back pain in undifferentiated spondyloarthropathy: a 1-year observational study , 2010, Annals of the rheumatic diseases.

[9]  R. Landewé,et al.  Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA , 2010, Annals of the rheumatic diseases.

[10]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[11]  W. Dixon,et al.  Extended Report , 2022 .

[12]  Stanley B. Cohen,et al.  Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate , 2010, Annals of the rheumatic diseases.

[13]  Anne Barton,et al.  Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment , 2010, Annals of the rheumatic diseases.

[14]  P. Emery,et al.  Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? , 2010, Annals of the rheumatic diseases.

[15]  E. Martı́n-Mola,et al.  Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. , 2010, Rheumatology.

[16]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[17]  F. Breedveld,et al.  The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis , 2010, Annals of the rheumatic diseases.

[18]  B. Bresnihan,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 , 2009, Annals of the rheumatic diseases.

[19]  A. Barton,et al.  Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population , 2009, Annals of the rheumatic diseases.

[20]  M. Dougados,et al.  Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial) , 2009, Annals of the rheumatic diseases.

[21]  A. Barton,et al.  No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort , 2009, Annals of the rheumatic diseases.

[22]  J. Barrett,et al.  Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease , 2009, Annals of the rheumatic diseases.

[23]  P. Emery,et al.  The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy , 2009, Annals of the rheumatic diseases.

[24]  John Bowes,et al.  PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population , 2009, Annals of the rheumatic diseases.

[25]  M. Dougados,et al.  Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008 , 2009, Annals of the rheumatic diseases.

[26]  P. Emery,et al.  A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools , 2009, Annals of the rheumatic diseases.

[27]  P. Emery,et al.  Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy , 2009, Annals of the rheumatic diseases.

[28]  R. Moots,et al.  Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial , 2009, Annals of the rheumatic diseases.

[29]  J. Staessen,et al.  Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial , 2009, The Lancet.

[30]  M. I. Perez,et al.  Treatment blood pressure targets for hypertension. , 2009, The Cochrane database of systematic reviews.

[31]  P. Emery,et al.  Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis international Society criteria: MRI entering centre stage , 2009, Annals of the rheumatic diseases.

[32]  F. Breedveld,et al.  Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. , 2009, Arthritis and rheumatism.

[33]  P. Emery,et al.  Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study , 2009, Annals of the rheumatic diseases.

[34]  P. Emery,et al.  Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis , 2009, Annals of the rheumatic diseases.

[35]  M. Dougados,et al.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal , 2009, Annals of the rheumatic diseases.

[36]  P. Emery,et al.  Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe , 2009, Annals of the rheumatic diseases.

[37]  F. Breedveld,et al.  Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients , 2009, Annals of the rheumatic diseases.

[38]  A. Tennant,et al.  Adaptation and cross-cultural validation of the rheumatoid arthritis work instability scale (RA–WIS) , 2008, Annals of the rheumatic diseases.

[39]  Michael J. Green,et al.  Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence , 2008, Annals of the rheumatic diseases.

[40]  Alexander M. Fraser,et al.  MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib , 2008, Annals of the rheumatic diseases.

[41]  A. Radjenovic,et al.  Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study , 2008, Annals of the rheumatic diseases.

[42]  D. M. van der Heijde,et al.  Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade , 2008, Annals of the rheumatic diseases.

[43]  M. Dougados,et al.  Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies , 2008, Annals of the rheumatic diseases.

[44]  B. Griffiths,et al.  The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus , 2008, Annals of the rheumatic diseases.

[45]  Olivier Meyer,et al.  Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study , 2008, Arthritis research & therapy.

[46]  J. Smolen,et al.  The importance of reporting disease activity states in rheumatoid arthritis clinical trials. , 2008, Arthritis and rheumatism.

[47]  F. Breedveld,et al.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial , 2008, The Lancet.

[48]  T. Ogihara,et al.  The Optimal Target Blood Pressure for Antihypertensive Treatment in Japanese Elderly Patients with High-Risk Hypertension: A Subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial , 2008, Hypertension Research.

[49]  P. Kerstens,et al.  Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial , 2008, Annals of the rheumatic diseases.

[50]  R. Turpin,et al.  Defining success in diabetes disease management: digging deeper in the data. , 2008, Disease management : DM.

[51]  R. Moses.  Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets. , 2008, Clinical therapeutics.

[52]  V. Strand,et al.  Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results , 2007, Annals of the rheumatic diseases.

[53]  D. M. van der Heijde,et al.  High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study , 2007, Annals of the rheumatic diseases.

[54]  R. Westhovens,et al.  Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. , 2008, Rheumatology.

[55]  Michael H Weisman,et al.  New therapies for treatment of rheumatoid arthritis , 2007, The Lancet.

[56]  J. Jacobs,et al.  Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility , 2007, Annals of the rheumatic diseases.

[57]  E. Keystone,et al.  Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. , 2007, Arthritis and rheumatism.

[58]  J. Jacobs,et al.  Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) , 2007, Annals of the rheumatic diseases.

[59]  G. Wiesmüller,et al.  Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone , 2007, Rheumatology International.

[60]  N. Shadick,et al.  Outcomes in rheumatoid arthritis: incorporating the patient perspective , 2007, Current opinion in rheumatology.

[61]  B. Combe.  Early rheumatoid arthritis: strategies for prevention and management. , 2007, Best practice & research. Clinical rheumatology.

[62]  E. G. de la Concha,et al.  Role of the MHC2TA gene in autoimmune diseases , 2006, Annals of the rheumatic diseases.

[63]  B Combe,et al.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[64]  J. Smolen,et al.  Remission of rheumatoid arthritis: should we care about definitions? , 2006, Clinical and experimental rheumatology.

[65]  D. Mikhailidis,et al.  Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study) , 2006, Current medical research and opinion.

[66]  J. Smolen,et al.  Krankheitsaktivitätsmessung bei rheumatoider Arthritis , 2006, Zeitschrift für Rheumatologie.

[67]  J. Smolen,et al.  [Measuring disease activity for rheumatoid arthritis]. , 2006, Zeitschrift fur Rheumatologie.

[68]  A. Silman,et al.  The British Society for Rheumatology Biologics Register , 2005, Annals of the rheumatic diseases.

[69]  D. Symmons,et al.  The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. , 2005, Health technology assessment.

[70]  P. V. van Riel,et al.  Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial , 2005, Annals of the rheumatic diseases.

[71]  M. Uffmann,et al.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.

[72]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[73]  F. Breedveld,et al.  Appropriate and effective management of rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[74]  T. Pincus,et al.  A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. , 2003, Clinical and experimental rheumatology.

[75]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[76]  E C Coles,et al.  Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[77]  J J Anderson,et al.  Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. , 2000, Arthritis and rheumatism.

[78]  A. Zwinderman,et al.  Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. , 1999, Arthritis and rheumatism.

[79]  M. V. van Leeuwen,et al.  Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. , 1998, British Journal of Rheumatology.

[80]  A. van der Heide,et al.  Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[81]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[82]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[83]  van der Heijde Dm,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .